S. 5513, Domestic Manufacturing Incentive with Tariff-Funded Subsidy. Quorum's AI analysis reads it as a trade-off: gains for some, costs for others.
S. 5513 · Mixed
What it does
This bill creates a 9-year pilot program requiring large hospitals to purchase at least 40% of their personal protective equipment and medical consumables from domestic manufacturers, with financial penalties (2–8% reimbursement cuts) for non-compliance. It funds hospital reimbursements through tariffs on imported medical supplies (phased to 300% ad valorem over 5 years) and offers tax credits to domestic PPE manufacturers and investors in PPE production facilities.
The analysis names Domestic PPE manufacturers (production tax credits + tariff-protected market access) — and 2 more groups — among the beneficiaries.
The trade-off
Tariff phase-in (10% →︎ 100% over 5 years) will progressively increase hospital procurement costs for imported PPE, potentially raising prices for patients and straining hospital budgets before domestic capacity fully scales.
The analysis put a high warning level on this bill. Transparency scores 72%, and the analysis found no provisions unrelated to the bill's subject.
Who is behind it
Filed by Bill Cassidy.
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.